In Argentum Pharmaceuticals LLC v. Novartis Pharmaceuticals Corp., [2018-2273] (April 23, 2020), the Federal Circuit dismissed the appeal, noting that the appellant remaining after settlement lacked Article III standing to appeal the PTAB’s IPR decision. The Federal Circuit said that … Continue reading Losing the Right to Challenge a Patent is not Enough to Confer Standing to Appeal IPR Decision